China meheco group announced that its subsidiary Tianfang Pharmaceutical recently received the pharmaceutical registration certificate for oseltamivir phosphate capsules issued by the National Medical Products Administration. This pharmaceutical is mainly used for the treatment of influenza A and B in adults and children aged 1 year and above, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and above.
中国医药：子公司天方药业获磷酸奥司他韦胶囊药品注册证书
China meheco group: Subsidiary Tianfang Pharmaceutical has received the pharmaceutical registration certificate for oseltamivir phosphate capsules.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated